During the webinar, Sarepta disclosed detailed liver adverse event data for its Elevidys treatment, revealing that ambulatory and non-ambulatory patients face similar risks of acute liver injury (ALI) in clinical settings. However, commercial non-ambulatory patients showed higher risk for liver hospitalizations and acute liver failure in the post-marketing environment. Despite these challenges, InvestingPro data shows the company maintains strong liquidity with a current ratio of 2.89, though it's currently burning through cash. The company indicated that an upcoming black box warning update to Elevidys' label will include an ALI warning for both ambulatory and non-ambulatory patients, addressing safety concerns that have emerged during the treatment's use.